Single‐cell atlas reveals heterogeneous response to FcRn blockade in anti‐AChR antibody‐positive generalised myasthenia gravis
Clinical and Translational Medicine · 2025
DOI: 10.1002/ctm2.70436 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Translational Medicine, 2025. Verfasst von Hui-Ning Li und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China. Hauptthemen laut MEDLINE: Receptors, Fc, Myasthenia Gravis, Histocompatibility Antigens Class I, Receptors, Cholinergic. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of Tianjin Province, National Natural Science Foundation of China.
Abstract (Originalsprache)
Background
Myasthenia gravis (MG) is an autoimmune disease predominantly driven by autoantibodies targeting acetylcholine receptor (AChR), resulting in muscle weakness. Efgartigimod, a neonatal Fc receptor (FcRn) blocker, reduces pathogenic immunoglobulin G in anti‐AChR antibody‐positive generalised MG (gMG). This study aimed to identify immune mechanisms underlying MG pathology and response to efgartigimod.
Methods
We constructed a single‐cell atlas of peripheral immune cells from treatment‐naïve and efgartigimod‐treated patients with gMG. Comprehensive immunophenotyping was performed to compare the clonal diversity of B‐ and T‐cell populations, alongside experimental validation to assess the activation of Th17‐related pathways before and after FcRn blockade.
Results
B cells in patients with gMG exhibit heightened activation and differentiation, while T cells display distinct pro‐inflammatory phenotypes. Enhanced intercellular signalling contributed to the pathogenicity associated with gMG. Efgartigimod mitigated upregulated antigen processing and presentation pathways in MG. Additionally, B‐cell clonal diversity and IGHG1‐bearing B‐cell receptors increased. Transcriptional factor alterations were noted in suboptimal responders. Regulation of T‐cell activity, particularly within Th17‐related pathways, was associated with remission rates.
Conclusions
These findings underscore immune heterogeneity and dynamics during efgartigimod treatment, providing mechanistic insights into therapeutic response in gMG. Key points Aberrant B cells and pro‐inflammatory T cells contribute critically to generalised myasthenia gravis (gMG) pathogenesis. Neonatal Fc receptor (FcRn) blockade induces immunoglobulin G (IgG) depletion feedback, reflected by increased class‐switched BCRs. Th17 cell proliferation is attenuated following FcRn blockade. Antigen processing and presentation pathways are downregulated after FcRn blockade in gMG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology, Tianjin Neurological Institute, Tianjin Medical University General Hospital, Tianjin, China.
- Tianjin Key Laboratory of Inflammatory Biology, Department of Pharmacology, School of Basic Medicine, Tianjin Medical University, Tianjin, China.
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Tianjin, China.
- Province and Ministry Co-Sponsored Collaborative Innovation Center for Medical Epigenetics, Department of Bioinformatics, School of Basic Medicine, Tianjin Medical University, Tianjin, China.
- Department of Neurology, Hainan General Hospital, Hainan Affiliated Hospital of Hainan Medical University, Haikou, China.
- Department of Neurology, National Clinical Research Center for Neurological Diseases of China, Beijing Tiantan Hospital, Capital Medical University, Beijing, China.
ORCID-Profile: Zhigang Cai, Chao Zhang
Förderung
- Natural Science Foundation of Tianjin Province
- National Natural Science Foundation of China
Zitieren
APA
Li, H. N., Liu, J., Huang, X. Y., Zhu, L., Liu, Z., Yang, C. S., Zhang, B., Huang, S., Shi, F. D., Cai, Z., & Zhang, C. (2025). Single‐cell atlas reveals heterogeneous response to FcRn blockade in anti‐AChR antibody‐positive generalised myasthenia gravis. Clinical and Translational Medicine. https://doi.org/10.1002/ctm2.70436
Vancouver
Li HN, Liu J, Huang XY, Zhu L, Liu Z, Yang CS, et al. Single‐cell atlas reveals heterogeneous response to FcRn blockade in anti‐AChR antibody‐positive generalised myasthenia gravis. Clinical and Translational Medicine. 2025. doi:10.1002/ctm2.70436
BibTeX
@article{Li2025,
author = {Li, Hui-Ning and Liu, Jingjing and Huang, Xiao-Yu and Zhu, Lijie and Liu, Zhirui and Yang, Chun-Sheng and Zhang, Bo and Huang, Shixiong and Shi, Fu-Dong and Cai, Zhigang and Zhang, Chao},
title = {Single‐cell atlas reveals heterogeneous response to FcRn blockade in anti‐AChR antibody‐positive generalised myasthenia gravis},
journal = {Clinical and Translational Medicine},
year = {2025},
doi = {10.1002/ctm2.70436}
}
EUVIMED